Want to see ES:RJF full AI Analyst Report?
Top Page
LABORATORIO REIG JOFRE
(BME:RJF)
Select Model
Select Model
Rating:51Neutral
Price Target:
€3.00
▲(11.94% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weakened financial performance, especially the sharp 2025 margin decline and negative free cash flow, alongside a higher (though still moderate) leverage profile. Technicals provide partial support with the stock trading above key moving averages and moderately positive momentum. Valuation remains a headwind due to the high P/E and low dividend yield.
Positive Factors
Business model diversification
A dual revenue model (branded/specialty medicines plus CDMO services) provides structural balance: product sales drive margin upside while contract manufacturing supplies recurring fee-based revenue and capacity utilization, reducing single-source demand risk and supporting steady cash flow over cycles.
Negative Factors
Sharp 2025 revenue & margin hit
A large year-on-year revenue decline and collapse in operating margins materially undermine sustainable earnings power. Such deterioration reduces retained earnings available for reinvestment and makes achieving prior returns difficult without clear signs of demand recovery or cost restructuring.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model diversification
A dual revenue model (branded/specialty medicines plus CDMO services) provides structural balance: product sales drive margin upside while contract manufacturing supplies recurring fee-based revenue and capacity utilization, reducing single-source demand risk and supporting steady cash flow over cycles.
Read all positive factors
LABORATORIO REIG JOFRE (RJF) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€219.84M
Dividend Yield0.73%
Average Volume (3M)6.22K
Price to Earnings (P/E)31.5
Beta (1Y)0.38
Revenue Growth-0.42%
EPS Growth4.56%
CountryES
Employees1,512
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.05
Shares Outstanding82,883,400
10 Day Avg. Volume5,547
30 Day Avg. Volume6,219
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)€358.45M
LABORATORIO REIG JOFRE Business Overview & Revenue Model
Company Description
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription dru...
How the Company Makes Money
RJF primarily makes money through (1) selling pharmaceutical products and healthcare items and (2) providing contract development and manufacturing services. Product-related revenue is generated from the commercialization of its own portfolio (inc...
LABORATORIO REIG JOFRE Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
68
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 331.26M | 331.10M | 338.89M | 316.09M | 271.15M | 236.23M |
| Gross Profit | 166.09M | 81.71M | 195.68M | 176.89M | 69.58M | 144.98M |
| EBITDA | 29.53M | 30.48M | 36.18M | 33.89M | 30.44M | 24.66M |
| Net Income | 4.39M | 5.02M | 10.38M | 9.41M | 8.11M | 5.09M |
Balance Sheet | ||||||
| Total Assets | 413.17M | 396.56M | 344.85M | 330.55M | 321.19M | 324.98M |
| Cash, Cash Equivalents and Short-Term Investments | 21.58M | 16.84M | 16.08M | 6.36M | 6.88M | 5.16M |
| Total Debt | 103.27M | 98.53M | 58.52M | 53.49M | 61.24M | 67.38M |
| Total Liabilities | 189.60M | 170.24M | 130.90M | 126.29M | 126.64M | 136.46M |
| Stockholders Equity | 221.28M | 218.07M | 213.97M | 204.35M | 194.63M | 188.59M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -13.78M | 10.56M | 6.34M | 4.75M | -5.26M |
| Operating Cash Flow | 0.00 | 1.51M | 31.34M | 19.11M | 16.15M | 14.50M |
| Investing Cash Flow | 0.00 | -17.82M | -31.96M | -12.88M | -12.72M | -34.70M |
| Financing Cash Flow | 0.00 | 16.31M | 5.59M | -7.16M | -2.04M | 13.67M |
LABORATORIO REIG JOFRE Technical Analysis
Negative
2.68
Price Trends
2.68
Negative
2.69
Negative
2.63
Positive
Market Momentum
>-0.01
Positive
40.81
Neutral
13.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Negative. The current price of 2.68 is below the 20-day moving average (MA) of 2.69, above the 50-day MA of 2.68, and above the 200-day MA of 2.63, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.81 is Neutral, neither overbought nor oversold. The STOCH value of 13.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:RJF.
LABORATORIO REIG JOFRE Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | €961.90M | 20.36 | 41.91% | 2.76% | 10.89% | 17.12% | |
70 Outperform | €2.97B | 16.20 | 27.84% | 1.33% | 3.21% | 39.34% | |
60 Neutral | €5.88B | 14.92 | 8.43% | 0.82% | -0.33% | 51.93% | |
58 Neutral | €1.40B | 10.43 | 18.19% | 2.82% | 31.88% | -20.09% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €219.84M | 31.52 | 3.14% | 0.73% | -0.42% | 4.56% | |
50 Neutral | €2.26B | 31.27 | 4.78% | 1.78% | 9.67% | 174.00% |
* General Sector Average
ES:RJF
LABORATORIO REIG JOFRE
2.64
-0.23
-7.92%
ES:ALM
Almirall
10.08
-0.86
-7.82%
ES:CBAV
Clinica Baviera
56.80
13.54
31.30%
ES:FAE
Faes Farma
4.43
0.23
5.55%
ES:GRF
Grifols
9.96
-2.11
-17.51%
ES:ROVI
Laboratorios Farmaceuticos Rovi
57.70
-0.88
-1.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.